Live Analyst Rating Changes 44045 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Priyanka Grover
JPM

Priyanka Grover

J.P. Morgan
Wall Street Analyst
★★☆☆☆
#2862
on 13Foresight · ranked by our own returns
23%
Success Rate
-8.6%
Average Return
5 of 22 calls profitable · -9.9% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 23% of Priyanka Grover's ratings turned a profit when each position was held for 1 year — averaging -8.6% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

22 Buy 2 Hold 2 Sell
Priyanka's Stock Coverage 10 ratings · 2026-10-20
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
RYTM
Rhythm Pharmaceuticals
 Oct 15, 2026 BUY Strong Buy
+45.7% avg upside
23 analysts
$145.00
64.36% Upside
 -2.1% ·
RCUS
Arcus Biosciences
 Oct 14, 2026 BUY Strong Buy
+60.5% avg upside
22 analysts
$41.00
85.19% Upside
 +1.3% ·
KURA
Kura Oncology
 Oct 13, 2026 BUY Strong Buy
+180.6% avg upside
27 analysts
$30.00
220.50% Upside
 -0.3% ·
NGNE
Neurogene
 Oct 08, 2026 BUY Buy
+104.9% avg upside
24 analysts
$60.00
148.34% Upside
 -8.8% ·
ELVN
Enliven Therapeutics
 Oct 01, 2026 BUY Strong Buy
+58.5% avg upside
18 analysts
$75.00
93.70% Upside
 -9.1% ·
BBOT
BridgeBio Oncology Therapeutics
 Sep 15, 2026 BUY Strong Buy
+673.2% avg upside
11 analysts
 — -41.6% ·
RXRX
Recursion Pharmaceuticals
 Sep 15, 2026 BUY Buy
+114.8% avg upside
12 analysts
 — +11.4% ·
NUVB
Nuvation Bio
 Sep 15, 2026 BUY Strong Buy
+194.0% avg upside
18 analysts
 — -22.6% ·
MREO
Mereo Biopharma Group Plc
 Sep 15, 2026 SELL Strong Buy
+1165.8% avg upside
11 analysts
 — -6.3% ·
RLAY
Relay Therapeutics
 Aug 14, 2026 BUY Strong Buy
+29.2% avg upside
21 analysts
$31.00
81.43% Upside
 -14.0% ·
🔒 5 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Priyanka Grover — Frequently Asked Questions
How accurate are Priyanka Grover's stock ratings?
Based on the calls 13Foresight could measure, about 18% of Priyanka's ratings were profitable over a one-year hold, with an average return of -9.8% per rating, or -11.1% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Priyanka ranked on 13Foresight?
Priyanka Grover is currently ranked #2862 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Priyanka cover?
Priyanka most recently has ratings on RYTM, RCUS, KURA, NGNE, ELVN, BBOT, RXRX, NUVB, MREO, RLAY. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.